Virax Biolabs Group Limited (VRAX)
Virax Biolabs Group Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Virax Biolabs Group Limited (VRAX) is a Biotechnology company based in GB with a market capitalization of $769K. Revenue declined 96.0% year-over-year and free cash flow was negative at -$5.2M. This page tracks VRAX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
GB · 17 employees · IPO Jul 21, 2022
Valuation
Valuation & price
$0.15as of May 17, 2026· -99.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.10
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$769K
Market cap
-96.0%
Revenue growth (YoY)
-838.2%
Gross margin
-$5.2M
Free cash flow (USD)
-$3.9M
Net debt
Net cash position
54.4%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2020 → 2025
Free cash flow by year
2020 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: Jul 1, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 16, 2026Filing
Shareholder Update
- 6-K filingJul 10, 2026Filing
Preferred Investment Option
- 6-K filingJul 9, 2026Filing
Commercial Supply Agreement
- Annual reportJul 2, 2026Filing
20-F Filed
- 6-K filingJun 24, 2026Filing
Share Consolidation
- Annual reportJun 12, 2026Filing
Annual Report Filed
- 6-K filingMay 26, 2026Filing
Positive Clinical Data Report
- 6-K filingMay 22, 2026Filing
Amended Memorandum and Articles
- 6-K filingApr 14, 2026Filing
Shareholder Letter
- 6-K filingApr 10, 2026Filing
Unregistered Sale of Equity Securities
Questions
Frequently asked questions
What is Virax Biolabs Group Limited's market cap?
Virax Biolabs Group Limited (VRAX) has a market capitalization of $769K.
What is VRAX's P/E ratio?
A meaningful P/E ratio is not available for VRAX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is VRAX's price-to-book (P/B) ratio?
VRAX trades at 0.10 times book value per share.
When did Virax Biolabs Group Limited last report earnings?
VRAX last reported earnings on July 1, 2026; the next date is not yet scheduled.
Are insiders buying VRAX stock?
SEC Form 4 filings show no open-market insider buys at Virax Biolabs Group Limited in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.